Targeted Molecular Therapies (Cetuximab And Bevacizumab) Do Not Induce Additional Hepatotoxicity: Preliminary Results Of A Case-Control Study

P. Pessaux (1) , F. Panaro (1) , S. Casnedi (2) , I. Zeca (1) , E. Marzano (1) , P. Bachellier (1) , D. Jaeck (1) , M.P. Chenard (2)

1 Hôpital de Hautepierre [Strasbourg]
2 HUS - Les Hôpitaux Universitaires de Strasbourg

To analyse the effects of the preoperative targeted molecular therapy (cetuximab (cetu) or bevacizumab (beva)) on non-tumorous liver parenchyma, and the clinical and biological outcome after liver resection for colorectal liver metastases (CLM).

Mots clés: hepatectomy; colorectal metastases; morbidity; hepatotoxicity; targeted molecular therapy; bevacizumab; cetuximab

P. Pessaux, F. Panaro, S. Casnedi, I. Zeca, E. Marzano, et al.. Targeted Molecular Therapies (Cetuximab And Bevacizumab) Do Not Induce Additional Hepatotoxicity: Preliminary Results Of A Case-Control Study. EJSO - European Journal of Surgical Oncology, 2010, 36 (6), pp.575. ⟨10.1016/j.ejso.2010.04.010⟩. ⟨hal-00599224⟩